Hunan Fangsheng Pharmaceutical Co., Ltd. Class ASSE: 603998

Announcement on Obtaining Summary Report of Phase III Clinical Trial for Pediatric Jingxing Anti-tussive Granules in Adults with Acute Tracheobronchitis (Syndrome of Wind-cold Transformation into Heat)

· Issued by Hunan Fangsheng Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Obtaining Summary Report of Phase III Clinical Trial for Pediatric Jingxing Anti-tussive Granules in Adults with Acute Tracheobronchitis (Syndrome of Wind-cold Transformation into Heat)

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis